CLAIM #40577 · Medtronic PLC (MDT) · 2025Q2 earnings call · Nov 19, 2024 · due Apr 25, 2025
“Full year, we expect operating margins to be 25.7%, up year-over-year by 10 basis points.”
Gary Corona · Interim CFO
In context
“xibility and your commitment to continue to grow earnings despite some of those potential headwinds that investors have been starting to worry about? GeoffMartha: Yes, Travis, thanks for the question. And yes, we are definitely committed to the earnings. I'll let Gary walk you through some of your specifics of your questions. . Gary Corona: Thanks, Geoff. We're pleased to raise our guidance on both revenue and EPS for the year as we continue to move, kind of, build momentum. There's a lot to be excited about and we're focused on driving durable, both revenue growth as well as restoring the earnings power of the company. On the margin front, what I want you to hear from us is there's no change to our margin expectations. In Q3, we expect margins of 25.6%, up 30 basis points year-over-year. Full year, we expect operating margins to be 25.7%, up year-over-year by 10 basis points. Gross margins will be up sequentially in both Q3 and Q4, and that will deliver our guidance. On the SG&A front, we'll drive leverage through a focus on our highest priorities, leveraging what we talked about before automation and digitization, we'll make some structural changes, and we have strong discipline on our discretionary expenses to help drive that margin expansion. You mentioned the early launches, and we're committed to investing behind those, both commercially and in R&D. So taken together, that mid-single-digit revenue growth will deliver upwards of 10%, EPS on a constant currency basis. You mentioned the foreign exchange. That will be a five-point headwind in line with what we've talked about before. And that will get us to the $5.44 to $5.50 guidance that we gave today. So o”
Verify independently
SEC filings for MDT ↗ · Claim quote is verbatim from the 2025Q2 earnings call.